Advanced search
Publication Cover
Leukemia & Lymphoma Volume 57, 2016 - Issue 10
Submit an article Journal homepage
395
Views
18
CrossRef citations to date
0
Altmetric
Letters to the Editor

A phase II study of the efficacy, safety, and determinants of response to 5-azacitidine (Vidaza®) in patients with chronic myelomonocytic leukemia

Srinivas K. TantravahiDivision of Hematology and Hematologic Malignancies, Huntsman Cancer Hospital, The University of Utah, Salt Lake City, UT, USA;
,
Philippe SzankasiDepartment of Pathology, The University of Utah and ARUP Laboratories, Salt Lake City, UT, USA;
,
Jamshid S. KhorashadDivision of Hematology and Hematologic Malignancies, Huntsman Cancer Hospital, The University of Utah, Salt Lake City, UT, USA;
,
Kim-Hien DaoOregon Health & Science University, Knight Cancer Institute, OR, USA
,
Tibor KovacsovicsDivision of Hematology and Hematologic Malignancies, Huntsman Cancer Hospital, The University of Utah, Salt Lake City, UT, USA;
,
Todd W. KelleyDepartment of Pathology, The University of Utah and ARUP Laboratories, Salt Lake City, UT, USA;
&
Michael W. DeiningerDivision of Hematology and Hematologic Malignancies, Huntsman Cancer Hospital, The University of Utah, Salt Lake City, UT, USA; Correspondence[email protected]
 show all
Pages 2441-2444 | Received 31 Aug 2015, Accepted 28 Dec 2015, Published online: 08 Feb 2016
 
Sample our Medicine, Dentistry, Nursing & Allied Health journals, sign in here to start your FREE access for 14 days
Click to increase image sizeClick to decrease image sizeFree first page

Acknowledgements

The authors thank all the patients and their families for participating in the study, nurses, and clinical research coordinators.

Potential conflict of interest

Disclosure forms provided by the authors are available with the full text of this article at http://dx.doi.org/10.3109/10428194.2016.1138295.

Funding information

This work was supported by a Specialized Center of Research Program Award (GCNCR0314A-UTAH to M.W.D) from The Leukemia & Lymphoma Society (LLS) and by The V Foundation for Cancer Research (to M.W.D). S.K.T is a recipient of 2013 Research Training Award for Fellows from the American Society of Hematology (ASH). J.S.K is a Special Fellow of the LLS and was supported by a Translational Research Training in Hematology Award from the ASH.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.